Samsrita Labs Q1 FY27 results: nil revenue, wider standalone loss of INR 31.47 lakh

Pat NegativeRevenue DeclineResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.9%Reaction day

₹12.26

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-5.9% vs market

Healthcare Service Provider peers, median of 26sector-2.0%-3.9% vs sector

On the reaction day the stock moved 5.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.9+0.1-5.9-2.0-3.9

Next day

-3.8+0.2-3.9-0.3-3.5

-3.8+0.6-4.3-0.3-3.5

-8.6-0.0-8.6-3.7-4.9

-4.2+0.5-4.7-2.3-1.9

-8.9+0.8-9.7-2.1-6.8

-9.1+0.6-9.7-0.2-8.9

15d

-2.0+1.3-3.2+1.7-3.6

—-1.4—-0.2—

-7.3-0.6-6.7-5.2-2.1

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q1 FY27 results (quarter ended 30 June 2026). Revenue from operations was nil against INR 1.81 lakh in Q4 FY26. Standalone net loss widened to INR 31.47 lakh (EPS minus 0.14) from INR 11.87 lakh in Q4 FY26. Consolidated loss narrowed to INR 18.87 lakh after positive share from two associates. Auditor MGR and Co issued an unqualified limited review report.

Likely market impact

Zero operating revenue and wider losses are negative signals; clean audit review offers limited comfort but stock may stay weak.